Lymphoma Australia yakabudirira kugamuchira rubatsiro rwepasi rose kubva kuAbbVie kuti iite hurukuro nenyanzvi dzeAustralia nedzepasi rose mu lymphoma uye chronic lymphocytic leukemia (CLL). Bvunzurudzo idzi dzichataura ruzivo rwazvino nezve lymphoma/CLL kiriniki miedzo uye zvidzidzo kubva pasirese uye dzakaratidzwa panguva yemusangano weASH. Hurukuro idzi dzichagoverwa pasi rose kuburikidza nemapoka ekukurudzira varwere.
Lymphoma Australia yakaita bvunzurudzo dzinosvika makumi mana mukati memazuva mana emusangano uye tinoda kupa kutenda nemoyo wese kubva kunharaunda yelymphoma / CLL kune wese akagovera nguva yavo, ruzivo uye hunyanzvi nesu.
B-cell Lymphoma
Dr Laurie Sehn – ASH Lymphoma Updates.
Dr Laurie Sehn vanobva kuBritish Columbia Cancer Center vanobva kuVancouver, Canada ndivo Sachigaro webhodhi rinoona nezvekurapa reInternational Lymphoma Coalition. Dr Sehn vakakurukura zvimwe zvezvakakosha mumishonga mitsva yakapihwa pamusangano weASH we lymphoma. Izvi zvaisanganisira Polatuzumab (antibody drug conjugate) yekuparadzira hombe B-cell lymphoma (DLBCL) neMosunetuzumab - (bispecific antibody) inoshandiswa kuB-cell isiri Hodgkin lymphomas.Dr Chan Cheah - Phase I Kudzidza TG-1701 Yakadzokazve kana Refractory B-cell Lymphoma.
A/Prof Chan Cheah, Consultant Haematologist, Sir Charles Gairdner Hospital, Hollywood Private Hospital & Blood Cancer Research WA, muPerth, Western Australia, vakakurukura mharidzo yeposter paASH yemuyedzo wakaitwa muAustralia uchishandisa chizvarwa chitsva cheBruton's Tyrosine Kinase. (BTK) inhibitor inonzi TG-1701 inoshandiswa kune varwere vane relapsed / refractor B-cell malignancies. Mushonga uyu wepamuromo unopiwa sechinhu chimwe chete chakabatana neumbralisib (PI3K inhibitor) uye ubiltuximab (glycoengineered anti-CD20 monoclonal antibody).Dr George Vanotevera – Lymphoma Updates.
Dr George Vanotevera ndiye Lymphoma/CLL Clinical Lead yeCambridge uye zvakare akabata akati wandei ekugadzwa kusanganisira sachigaro weUK CLL foramu. Dr Follows vakakurukura nezvekuvandudzwa kwelymphoma zvakaunzwa panguva yemusangano we ASH wekufarira. Izvi zvaisanganisira kuyedza kwechikamu chekutanga uchishandisa mushonga mutsva unonzi Monunetuzumab uri bispecific monoclonal antibody inonangana neCD3 neCD20 uye zvakakonzera mhinduro dzakasimba muvarwere vane kudzoka kana kuramba B-cell non-Hodgkin lymphoma, kusanganisira varwere vakadzoka kubva kuCAR T. - cell therapy.
Dr Stephen Schuste - Mosunetuzumab inokonzera kuregererwa kwakakwana kwevarwere vane B-cell isiri Hodgkin lymphoma.
Iyo bispecific monoclonal antibody Mosunetuzumab, iyo inonangana neCD3 neCD20, yakatungamira kumhinduro dzakasimba muvarwere vane B-cell non-Hodgkin lymphoma (NHL), kunyangwe kune avo vaive nechirwere chakadzoserwa kana kuramba chimeric antigen receptor (CAR) T- cell therapy. Dr Schuste vanokurukura nezvechidzidzo cheI/Ib chirikuenderera mberi (GO29781; NCT02500407) chemosunetuzumab muvarwere vane B-cell non-Hodgkin lymphoma (NHL), avo vakadzokororwa/refractory (R/R) kuCAR-T marapiro kana kune avo kunonoka mukurapa kunoshanda hakusanganisi nzira iyi. Yekutanga dhata rutsigiro kuti mosunetuzumab ine kushivirira kwakanaka uye kusimba kwesimba mu pre-yakarapwa R/R B-cell NHL.
Dr John Leonard - anosimbisa kubva kumusangano welymphoma.
Dr Leonard vakakurukura maonero avo ehunyanzvi kubva mumharidzo dze lymphoma panguva yemusangano. Akakurukura nyaya dzakati wandei dzaisanganisira: • Follicular lymphoma – chemo free regimens • Diffuse Large B-cell Lymphoma – utano hwemapfupa muvarwere mushure meR-CHOP neCAR T-cell therapy • Mantle Cell Lymphoma – mishonga mitsva yakasanganiswa nechemotherapy • Kuongororwa ropa kweDNA • Mishonga yeLymphoma
Chronic Lymphocytic Leukemia (CLL) uye Diki Lymphocytic Leukemia (SLL)
Dr Brian Koffman - CLL inogadziridza & kumiririra murwere.
Dr. Koffman, chiremba anozivikanwa zvikuru, mudzidzisi uye purofesa wekiriniki akashandura murwere weCLL, akazvipira kudzidzisa nekubatsira nharaunda yeCLL kubvira paakaongororwa muna 2005. Dr. Koffman anotenda kuti chimiro chake chechipiri sechiremba uye murwere chinopa zvakasiyana-siyana. ruzivo uye kunzwisisa izvo zvinomubvumira kuti ape tsananguro dzakajeka dzenyaya dzakaoma uye kutsigira vamwe vake varwere uye kuzivisa vaanoshanda navo vehutano. Izvi zvinonyanya kukosha tichitarisa kukurumidza kuchinja kwemaitiro ekurapa. Dr Koffman ndivo muvambi weCLL Society, USA. Dr Koffman vakakurukura nezve CLL zvigadziriso kubva kumusangano zvinosanganisira kuvandudzwa nezveCAR T-cell therapy, ibrutinib, acalabrutinib, kutevedzana kwemishonga uye akasiyana siyana kurapa. Akakurukurawo hutungamiri hwakanaka hweCLL, kusanganisira kuongororwa kwemajini vasati varapwa uye avo varwere vane chirwere chisingachinji, 17p del haifaniri kuva nekemotherapy, pane kurapa kwakananga.
Prof John Gribben naDeborah Sims - Pfupiso yekurapa kweCLL.
Prof Gribben vakakurukura maonero avo ezvekuvandudzwa kubva kumusangano uko akawanda emharidzo akasimbisa kuti marapiro ari kushandiswa akanaka sezvo kwave nenguva yakareba ichitevera. Nekutevera kwenguva refu kunouyawo ruzivo rwehutsva hutsva hunogona kuoneka. Tinogona ipapo kudzidzisa varwere zvirinani nekuve neruzivo rwuri nani rwezvatingatarisira. Akakurukurawo nezve chizvarwa chitsva chemishonga yekurapa yakaunzwa, kwete muCLL chete, asi mamwe lymphomas akadai seFollicular lymphoma & Mantle cell lymphoma. Kune zvakare akawanda ekutanga echikamu chekiriniki miedzo nemishonga mitsva inoratidza chivimbiso. Chinetso chinotevera ndechekuti neaya matsva ekurapa uye akasanganiswa marapirwo, anouya yakawedzera mari yehutano masisitimu.
Prof Stephan Stilgenbauer naDeborah Sims - Zvidzoreso pane manejimendi eCLL/SLL.
Prof Stilgenbauer vakapa muchidimbu nezvekuvandudzwa kwekurapa kwevarwere vane CLL/SLL kubva kumusangano weASH. Anotaura nezvekushandiswa kwemishonga inoverengeka seanoshanda ega uye mumisanganiswa ari kuve nemhedzisiro yakakosha kune varwere, kunyanya avo vane chirwere chisina kuchinjika uye nekudaro havapindure kune yechinyakare chemotherapy-based management. Kurapa kweramangwana kweCLL/SLL kungave kwekuti chemotherapy inogona kuve yechipiri kana yechitatu mutsara kurapwa.
A/Prof Constantine Tam naDeborah Sims - CLL & Mantle Cell Lymphoma.
A/Prof Constantine Tam, Peter MacCallum Cancer Center, RMH & St Vincent's Hospital vakataura naDeborah Sims, anobva kuLymphoma Australia. Dr. Akapa mhedziso yemharidzo dzake nhatu dzakarumbidzwa zvikuru dzeChronic Lymphocytic Leukemia (CLL) & Diki Lymphocytic Lymphoma (SLL).
Dr George Vanotevera - CLL inogadziridza.
Dr George Follows vanobva kuUK vakataura neLymphoma Australia pamusangano weAmerican Society of Hematology (ASH) wakaitwa muOrlando, USA nguva pfupi yadarika. Dr Follows ndiye Lymphoma/CLL Clinical Lead yeCambridge uye zvakare akabata akati wandei ekugadzwa kusanganisira sachigaro weUK CLL foramu. Akakurukura nezvekuvandudzwa patsvagiridzo yazvino uye mhedzisiro yezvidzidzo yakapihwa pamusangano weASH paCLL.
Dr Nitin Jain naDeborah Sims - Ibrutinib & Venetoclax mune varwere vane CLL.
Dr Nitan Jain ndiMubatanidzwa Muzvinafundo muDhipatimendi reLeukemia paYunivhesiti yeTexas MD Anderson Cancer Center muHouston, Texas, USA. Dr Nitan akakurukura mharidzo dzake mbiri panguva yemusangano weASH wezvidzidzo zviviri zvakaitwa kuMD Anderson Cancer Center vachishandisa yakasanganiswa Ibrutinib uye venetoclax nevarwere vane chronic lymphocytic leukemia (CLL) mukurapa kwekutanga uye avo vane chirwere chekudzokazve / chinoramba. Migumisiro yakaratidza kuti mumapoka ose maviri kurapwa kwakabatanidzwa uchishandisa ibrutinib uye venetoclax inobudirira chemotherapy-isina oral regimen kune varwere vane CLL uye zvimwe zvidzidzo zvichange zvichienderera mberi.
Dr Tanya Siddiqi - CAR T-sero mune yakadzokororwa / refractory CLL.
Dr Tanya Siddiqi ndiye Mutungamiriri, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center uye A/Prof Dhipatimendi reHematology & Hematopoietic Transplantation paGuta reHope National Medical Center, Duarte, USA. Dr Siddiqi vakakurukura mharidzo yavo panguva yemusangano wechikamu chekutanga chekurapa varwere vakadzokera shure kana vanoramba vane CLL. Vese varwere vakambogamuchira kanenge 3 marapirwo akajairwa, kusanganisira ibrutinib uye hafu yevarwere vakagamuchirawo venetoclax. Chidzidzo ichi chakabata varwere makumi maviri nevatatu neCAR T-cell therapy apo vanopfuura makumi masere muzana vakawana mhinduro dzakasimba mukati memwedzi mitanhatu. Kutevera kunoenderera mberi.
Prof John Seymour - Pfupiso yeChidzidzo cheMurano - CLL/SLL.
Prof Seymour vakapa ongororo yemakore mana yeongororo yeMurano inosimbisa kubatsirwa kwakagara kwenguva shoma Venetoclax & rituximab mukudzokazve kana refractory chronic lymphocytic leukemia (CLL). Venetoclax (Ven) inonyanya kusarudzwa oral inhibitor yekiyi apoptosis regulator BCL-2, iyo yakanyanyisa kuratidzwa muCLL. MURANO (a randomized Phase III study) yakaenzanisa yakatarwa-nguva VenR ine standard bendamustine-rituximab (BR) muR/R CLL. Iyo yepamusoro yekufambira mberi-isina kupona (PFS) yeVenR inopesana neBR yakasimbiswa mukutanga kusati kwarongwa kuongororwa (Seymour et al. N Engl J Med 2018); kuenderera mberi kwePFS kubatsirwa kwakaonekwa nekutevera kwenguva refu uye mushure mekunge varwere vese vapedza kurapa.
Prof Peter Hillmen - Matambudziko muCLL/SLL kurapwa mamiriro.
Prof Hillman vanokurukura mamwe ematambudziko ekukurumidza kuchinja kwekurapa mamiriro eCLL/SLL ane akawanda manyoro ekurapa pamusika.
Prof Peter Hillmen - CLL inogadziridza kubva kuASH 2019.
Prof Hillmen vakakurukura zvimwe zvezvakanyanya kukosha kubva kumusangano wezvitsva zviedzo zvekurapa zvakashandiswa munzvimbo yekutanga zvakaratidzwa zvakaratidza mhedzisiro nekushandiswa kweibrutinib (BTK inhibitor), acalabrutinib (new generation BTK inhibitor), venetoclax (BCL2 inhibitor). ) uye kushandiswa kwemishonga yakasanganiswa. Akakurukurawo nezvemiedzo yekiriniki munzvimbo yakadzokororwa inoratidza mhedzisiro yakanaka yaisanganisira CAR T-cell therapy. Ndatenda kuLeukemia Care nekugovana hurukuro neLymphoma Australia.
Prof Miles Prince – Genetic test (CLL/SLL) & CAR T-cell therapy.
Prof Prince vakakurukura pfungwa dzavo dzemisoro mikuru yekufarira lymphoma kubva kumusangano. Akakurukura kuti nzira yakanakisa yekurapa lymphoma yemurwere, kuongororwa kwavo kunoda kunzwisiswa nekuzivikanwa zvizere. Zvakaratidzwa kuti varwere vanoonekwa kuti vane CLL/SLL vanofanira kuongororwa genetic vasati vawana kurapwa. Varwere vasina kuchinja uye TP53 yakashandura CLL / SLL, chemotherapy yakaratidza kuti haina kushanda kune iri boka revarwere. MuUSA neUK (uye dzimwe nyika dzekuEurope) varwere vanopihwa mari yekugamuchira Ibrutinib yekumberi, zvisinei izvi hazvisati zviri izvo muAustralia, uko varwere vanowana chemo-immunotherapy uye ibrutinib mumutsara wechipiri kurapwa.
Diffuse Huru B-cell Lymphoma (DLBCL)
A/Prof Chan Cheah – Aggressive Lymphoma, Diffuse Large B Cell lymphomas.
A/Prof Cheah anodzokorora bepa "Aggressive Lymphoma (Diffuse Large B-cell uye mamwe ane hukasha b-cell asiri-Hodgkin lymphomas) - anobva kune angangove emiedzo yekiriniki: optimizing frontline chemotherapy" musangano wakaitwa neSvondo 8 Zvita kuASH 2019.
Dr Jason Westin - Diffuse Yakakura B-cell Lymphoma inogadziridza & iyo Smart Kutanga Chidzidzo.
Dr Westin vakakurukura zvimwe zvezvakakosha kubva kumusangano muDLBCL kusanganisira CAR T-cell therapy uye zvigadziriso kubva kuzvidzidzo zvinoshandisa mashoma chemotherapy uye nekudaro kuvandudza chepfu mhedzisiro yevarwere.
Follicular Lymphoma
Dr Loretta Nastoupil - Follicular lymphoma kudzidza - Chikamu 1.
Dr Nastoupil vachikurukura mhedzisiro yechikamu chechipiri chekudzidza kweObintuzumab (rudzi rwechipiri anti-CD20 monoclonal antibody) uye Lenalidamide (immunomodulatory agent) mune yaimbova isina kurapwa, yakakwirira bundu mutoro FL. Uku kusanganiswa kwemishonga kwakaonekwa kuti kwakanyatso kushivirirwa uye kunoshanda mukudzidza kwekare kune varwere vanobatwa mukudzokazve kana kuti refractory FL.
Dr Loretta Nastoupil - Follicular lymphoma kudzidza - Chikamu 2.
Dr Nastoupil vakakurukura mhedzisiro yechikamu chechipiri chekudzidza kweObintuzumab (type II anti-CD20 monoclonal antibody) uye Lenalidamide (immunomodulatory agent) mune yaimbova isina kurapwa, yakakura bundu mutoro FL. Kuwedzera kudzidza kweiyi inoshanda, immune therapy nzira mune isina kurapwa FL inotenderwa. Dr Nastoupil vanokurukura zvikonzero zveiyi nzira inoshanda uye inotenderwa kune chero huwandu hwevarwere vane Follicular lymphoma.
A/Prof Chan Cheah - Follicular lymphoma clinical trial update.
Dr Cheah vakakurukura mharidzo yakapihwa naDr Loretta Nastoupil kubva kuMD Anderson Cancer Center, Texas panguva yemusangano weASH 2019. Chidzidzo chechikamu chechipiri chakatarisa kurapa vasati varapwa Follicular lymphoma varwere vane Obintuzumab (type II anti-CD20 monoclonal antibody) uye Lenalidamide (immunomodulatory agent), ine bundu rakakura. Musanganiswa wekurapa uyu wakaonekwa uchitenderwa zvakanaka uye unoshanda muongororo yapfuura yevarwere vakarapwa vakadzokororwa kana kuti refractory FL yakaitwa paMD Anderson Cancer Center naProf Nathan Fowler (RELEVANCE kudzidza).
Dr Allison Barraclough -Nivolumab + Rituximab muFirst-line Follicular Lymphoma.
Dr Barraclough vakakurukura mhedzisiro yenguva pfupi yekutanga muchikamu chechipiri chekudzidza, icho chinotungamirwa naDr Eliza Hawkes, maneja wepamberi wevarwere vane nhanho 1-3A follicular lymphoma. Chidzidzo ichi chinoshandisa musanganiswa immune therapy nzira chete, iyo yanga yamboyedzwa kare mukudzokororwa kurongeka. Varwere vanogashira nivolumab kwemavhiki ekutanga e8 chete uye kana vakawana mhinduro yakakwana, inoenderera neiyo imwe mumiriri nivolumab. Kune avo vakangowana mhinduro shoma vaizoenda pakuva nemusanganiswa pa nivolumab uye rituximab. Mhedzisiro yaive yakanaka pachiyero chekupindura (ORR) che80% uye inopfuura hafu yevarwere ava vakawana mhinduro yakakwana (CR). Paive neiyo yakaderera toxicity mbiri, apo varwere vazhinji vaive vachiri kukwanisa kushanda nekuenderera mberi nehupenyu hwemazuva ese
Mantle Cell Lymphoma
Dr Sasanka Handunetti - Mantle Cell Lymphoma (Kuvandudzwa kwechidzidzo cheAIM).
Dr Handunetti vakakurukura mharidzo yavo pamusoro pekuvandudzwa kwemakore matatu kwechikamu chechipiri cheAIM chidzidzo (TAM, et al, NEJM 2018) chakaitwa paPeter MacCallum Cancer Center muMelbourne, vachishandisa musanganiswa BTK inhibitor ibrutinib uye BCL-2 inhibitor venetoclax therapy muvarwere vane urombo hunoreva mantle cell lymphoma (MCL). Mhinduro dzakaratidza kufambira mberi kwepakati kusununguka kwemwedzi makumi maviri nepfumbamwe. Yakasimudza mubvunzo wekuti pane mukana wenguva shoma yakanangwa-mumiririri kurapa mukutarisira kudzokororwa kana kuramba MCL.
Prof Steven Le Gouill - Mantle Cell Lymphoma kudzidza.
Prof Le Gouill vakakurukura chikamu chavo chekudzidza cheMCL ichangobva kuwanikwa vachishandisa Ibrutinib, Venetoclax uye Obintuzumab izvo zvakamboratidzwa kuti zvine humbowo mukudzoreredza/kuramba kurongeka senge vamiririri uye pamwe chete mune yakadzokororwa/kuramba (R/R) MCL. . Akapawo mhedziso yehutano hwehutano hwevarwere vane MCL kune murwere mudiki uye murwere akwegura mune zvose zviri mberi uye R / R kutarisira.
Prof Simon Rule - Mantle Cell Lymphoma Update.
Prof Simon Rule akakurukura mharidzo yake yeposita pamusangano achitarisa 7.5 gore rekutevera kwevarwere vane MCL yakadzoka zvakare kana kuti refractory avo varwere ve ibrutinib (BTK inhibitor) yakaratidza nhamba inokosha yevarwere vachiri mukuregererwa kupfuura makore mashanu. Yakaratidzawo kuti varwere vakagamuchira Ibrutinib mumitsara yepakutanga yerapi vaiva nemhinduro iri nani, pane avo vakagamuchira lateistique.
KTE-X19: A CAR T-Cell Sarudzo yeMantle Cell Lymphoma?
Zvikamu makumi mapfumbamwe nenhatu kubva muzana zvevarwere vane relapsed / refractory mantle cell lymphoma (MCL) vakapindura kurapwa neKTE-X19, autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, maererano nemigumisiro kubva mukuedza kweZUMA-2 yakaratidzwa. paMusangano Wepagore we2019 ASH.
Hodgkin Lymphoma
Dr Jessica Hochberg - Chemotherapy, Vechidiki Vakuru & Hodgkin Lymphoma.
Kurapa kwemishonga ichangobva kuongororwa Hodgkin Lymphoma yakakwirira pamwe nekushandiswa kwakasanganiswa kwechemoradiotherapy. Nekudaro, izvi zvinowanzokonzera kukanganisa kwakanyanya kwemuviri uye psychosocial basa iro rinogona kukanganisa zvakanyanya kunaka kwehupenyu pakati pevanopona. Kuwedzerwa kweBrentuximab vedotin uye Rituximab kusanganisa njodzi yakagadziriswa chemotherapy (isina cyclophosphamide, etoposide kana bleomycin) yeHodgkin Lymphoma ichangobva kuongororwa inoratidzika yakachengeteka kuvana, vechidiki uye vechidiki. Mhedzisiro yedu inoratidza vimbiso yakakosha ine CR mwero we100%, 58% nekukurumidza kupindura kwekutanga uye kuderera kukuru mukushandiswa kwechepfu chemotherapy nemwaranzi. Iyo EFS/OS kusvika parizvino ndeye 100% ine yepakati yekutevera nguva yemakore anopfuura 3.5.
Prof Andrew Evens - HoLISTIC Hodgkin Lymphoma International Chidzidzo.
Prof Evens inhengo inoshingaira yeHoLISTIC (Hodgkin Lymphoma International Study for Individual Care) - sangano repasi rose rinobatanidza boka renyanzvi dzakasiyana-siyana kubva pasirese kuti dziongorore zvakatanhamara zveHodgkin lymphoma prognosis, epidemiology, kurapwa, kupona uye hutano. mumazera ose. Vari kuwiriranisa data remurwere wega wega kubva kune anopfuura makumi maviri emazuva ano miedzo yekiriniki kubva kuNorth America neEurope yeese mazera pamwe ne20 masangano uye edunhu reHodgkin lymphoma registries, uye nharaunda yakakura oncology tsika. Chinangwa chavo ndechekusimudzira kuita sarudzo kune vana uye vakuru veHodgkin lymphoma varwere nevapepi, vachipihwa kuwedzera nzira dzekurapa uye nekushaikwa kwe data rakazara uye renguva refu rekufungidzira.
Dr Stephen Ansell naDeborah Sims - Hodgkin Lymphoma.
Dr Ansell inyanzvi inotungamira mune isiri Hodgkin lymphoma neHodgkin lymphoma paMayo Clinic, USA. Dr Ansell vakataura nezve Hodgkin lymphoma - front line therapy session kuASH yavakanga vachangobva kupinda. Chidzidzo ichi chakaratidza kuyedzwa kwekiriniki uko kwakave nekumwe kushandiswa mune zvitsva marapirwo pamberi-mutsetse kugadzika, uko kuwedzera Brentuximab Vedotin & a PD-1 inhibitor uye kuderedza imwe yeyakajairwa chemotherapy yaive bleomycin, yakaratidza mhedzisiro. Mhedzisiro yacho zvakare yakadzora chepfu kune varwere vanowana kurapwa uku mukuenzanisa neyakajairwa kurapwa. Kurapa kwakajairwa muHodgkin lymphoma kune yakakwira pamusoro peyese mazinga emhinduro apo vanenge 90% varwere vanosvika pamhinduro yakakwana yemetabolism. Miedzo mizhinji muHodgkin lymphoma parizvino yakanangana nekudzikisa huturu mbiri uye mhedzisiro yevarwere ava.
Marginal Zone Lymphoma
Dr Sasanka Handunetti - Chikamu II Chidzidzo muKudzokororwa kana Refractory Marginal Zone Lymphoma.
Dr Handunetti vakakurukura mharidzo yeposita kubva kuboka paPeter MacCallum Cancer Center panguva yemusangano wekushandiswa kwebrutinib pamwe chete nevenetoclax kune varwere vane kudzokazve kana kuti refractory Marginal Zone Lymphoma (MZL). MZL chirwere chisingarapike chekuti hapana chiyero chekurapa kwekutarisira mukudzoka zvakare kana kumisa kumisa. Mishonga miviri iyi yakaonekwa iine humbowo hwekuita uye kushivirira se monotherapies (vamiriri vamwechete) uye chidzidzo ichi chakanangana nekuongorora mhinduro semusanganiswa wekurapa.
Central Nervous System Lymphoma
Dr Katherine Lewis – Primary Central Nervous System Lymphoma (PCNSL).
Dr Lewis vakakurukura nezve poster mharidzo paASH 2019 yaitarisa mhedzisiro yevarwere vane primary kana yechipiri central nerve system (brain and spine) lymphoma yakarapwa neIbrutinib (BTK inhibitor). Iyi lymphoma isingawanzo uye ine hutsinye apo boka revarwere rine chirwere chisina kunaka uye rinowanzorapwa neine intensive combination chemotherapy regimens. Ichi chaive chidzidzo chekudzoka kwakaunganidza ruzivo kubva mhiri kweAustralia neNew Zealand yevarwere gumi nevatanhatu vakarapwa ne monotherapy Ibrutinib mune yakadzokororwa / refractory marongero. Kunyange zvazvo nhamba shomanana yevarwere, migumisiro yacho yakanga ichivimbisa, nemhinduro dzehuwandu kusvika ku16%.
Waldenstrom's Macroglobulinemia
Prof Mathias Rummel – Waldenstrom's Macroglobulinemia & the StiL muedzo.
Inovhara iyo 2-gore mhedzisiro post iyo StiL chidzidzo ichitarisa kugadzirisa Rituximab vs kuona post bendamustine-rituximab. Mibairo inoratidza kuti kuchengetedza rituximab hakugadzirise kupona kwese. Prof Rummel vanopawo tarisiro yekutonga kwazvino kweWM.
T-cell Lymphoma
Peripheral T-cell Lymphoma
Dr Jasmine Zain, MD - vanokurukura zvidzidzo zvinokatyamadza muPTCL zvakaratidzwa paASH 2019.
(Ndinokutendai OBRoncology).
Dr. Zain, Mutungamiriri weT-cell Lymphoma Program, Dhipatimendi reHematology uye Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, Guta reTariro, inokurukura zvidzidzo zvinonakidza mukurapa kweperipheral T-cell lymphoma (PTCL) yakaratidzwa pa ASH. 2019.
Dr Jasmine Zain - Maitiro ekurapa kweperipheral T-cell lymphoma akashanduka.
(Ndinokutendai OBRoncology).
Dr. Zain, Mutungamiriri weT-cell Lymphoma Program, Dhipatimendi reHematology uye Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, Guta reTariro, anofunga kuti peripheral T-cell lymphoma (PCL) therapy yakashanduka sei mumakore achangopfuura.
Dr Jasmine Zain - Novel nzira dzekurapa PTCL kusanganisira CAR T-cell therapy.
(Ndinokutendai OBRoncology).
Dr. Zain, Mutungamiriri weT-cell Lymphoma Program, Dhipatimendi reHematology uye Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, Guta reTariro, inotitaurira nezveimwe nzira itsva mukugadzirwa kwekurapa kweperipheral T-cell lymphoma ( PTCL).
Dr Timothy Illidge, vanotsanangura chinangwa chekunangana nePTCL.
(Ndinokutendai OBRoncology).
Dr. Illidge, Purofesa weTargeted Therapy uye Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, inotsanangura chinangwa chekunangisa peripheral t-cell lymphoma (PTCL).
